Dalziel J E, Spencer N J, Dunstan K E, Lynch A T, Haggarty N W, Gopal P K, Roy N C
Food Nutrition & Health Team, Food & Bio-based Products Group, AgResearch, Grasslands Research Centre, Private Bag 11008, Palmerston North 4442, New Zealand.
Food Funct. 2014 Nov;5(11):2768-74. doi: 10.1039/c4fo00193a.
Beta-casomorphin-5 (βCM-5) is a milk-derived bioactive peptide that slows gastro-intestinal transit (GIT) in vivo and blocks the peristaltic reflex in the guinea pig colon in vitro. We wanted to establish an in vitro model system in which effects of dairy-derived substances containing opioid peptides on intestinal motility can be assessed and used to predict in vivo outcomes. Because βCM-5 is an opioid agonist that acts on enteric neurons, we used this substance to compare two different isolated colonic tissue preparations to determine which would more closely mimic the in vivo response previously reported in the literature. We compared and characterized the effects of βCM-5 on spontaneous contractions in isolated segments of distal colon (1 cm length) compared with propagating contractions along the isolated intact large intestine (22 cm length). In short segments of distal colon, βCM-5 increased the tension and frequency of spontaneous contractions in a concentration-dependent manner. At 20 μM βCM-5 tension increased by 71 ± 17% and the frequency doubled (n = 9), effects inhibited by naloxone (n = 7) and therefore mediated by opioid receptors. In contrast 20 μM βCM-5 disrupted propagating contractions in the large intestine preparation. At 20 μM βCM-5 reduced the proportion of contractions initiated in the proximal colon reaching the rectum by 83 ± 11% (n = 5) and this effect was also inhibited by naloxone, consistent with altered GIT reported in vivo. Our results demonstrate that the isolated whole large intestine provides an ideal preparation that mimics the reduced propagation of GIT in vivo in response to an opioid agonist, whereas short colon segments did not. The findings of the current study reveal that preserving large segments of intact large intestine, and hence intact enteric neural circuitry provides an ideal in vitro model to investigate the effect of opioid receptor modulators on intestinal transit.
β-酪蛋白衍生吗啡肽-5(βCM-5)是一种源自牛奶的生物活性肽,它在体内会减缓胃肠蠕动(GIT),并在体外阻断豚鼠结肠的蠕动反射。我们希望建立一种体外模型系统,借此评估含有阿片肽的乳制品衍生物质对肠道蠕动的影响,并用于预测体内结果。由于βCM-5是一种作用于肠神经元的阿片类激动剂,我们使用该物质比较两种不同的离体结肠组织制剂,以确定哪种制剂能更紧密地模拟先前文献中报道的体内反应。我们比较并描述了βCM-5对离体远端结肠段(1厘米长)自发收缩的影响,并与沿离体完整大肠(22厘米长)的传播性收缩进行了比较。在远端结肠的短节段中,βCM-5以浓度依赖性方式增加自发收缩的张力和频率。在20μMβCM-5时,张力增加了71±17%,频率翻倍(n = 9),纳洛酮可抑制这些作用(n = 7),因此是由阿片受体介导的。相比之下,20μMβCM-5破坏了大肠制剂中的传播性收缩。在20μMβCM-5时,近端结肠起始的收缩到达直肠的比例降低了83±11%(n = 5),且这种作用也被纳洛酮抑制,这与体内报道的GIT改变一致。我们的结果表明,离体的整个大肠提供了一种理想的制剂,能够模拟体内因阿片类激动剂而导致的GIT传播减少,而短结肠段则不能。当前研究的结果表明,保留大片完整的大肠,进而保留完整的肠神经回路,为研究阿片受体调节剂对肠道转运的影响提供了理想的体外模型。